Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1991-5-9
|
| pubmed:abstractText |
A large number of pharmacological trials have been carried out, attempting to reduce the mortality (10-15%) in the year following of an acute myocardial infarction (MI) and/or the recurrence of ischemic events. Thrombolytic therapy and beta-blockade are the only interventions to be associated with a significant decrease in cardiac mortality. Early intervention with intravenous beta-blockers aims at limiting infarct size and at decreasing mortality. The Swedish study using intravenous (15 mg) followed by oral (200 mg/day) metoprolol showed a 36% reduction in mortality after the first week, a benefit persisting after 1 year. The combination of streptokinase and intravenous atenolol is safe and may be beneficial in selected patients. Large-scale controlled multicenter studies have shown that beta-blockers introduced within the first 3 days after acute MI significantly reduce total mortality and/or sudden death in the year following the acute event. Some of these studies demonstrate a reduction in recurrence of MI. The reduction (averaging 25%) in mortality may be explained by the anti-ischemic action of beta-blockers and the prevention of arrhythmia-induced death. Introduced early, beta-blockers may reduce the size of the initial MI as well as subsequent infarction and/or ischemia. Furthermore the antistress action of beta-blockers results in a decrease in free fatty acids, with their untoward effect in acute MI. Antiplatelet aggregation may also play a role. These properties of beta-blocking agents should be utilized in every patient with acute MI in the absence of any major contraindication. Elective indications include patients with hypertension, angina pectoris, and/or ventricular arrhythmias.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0160-2446
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16 Suppl 6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S50-4
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading |
pubmed-meshheading:1707116-Adrenergic beta-Antagonists,
pubmed-meshheading:1707116-Humans,
pubmed-meshheading:1707116-Myocardial Infarction,
pubmed-meshheading:1707116-Predictive Value of Tests,
pubmed-meshheading:1707116-Prognosis,
pubmed-meshheading:1707116-Recurrence,
pubmed-meshheading:1707116-Risk Factors
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Secondary prevention after myocardial infarction: in favor of beta-blockers.
|
| pubmed:affiliation |
Department of Cardiology, University of Marseille, School of Medicine, Hôpital Nord, France.
|
| pubmed:publicationType |
Journal Article,
Review
|